Descriptive study results for low-dose cyclophosphamide with bortezomib and low-dose dexamethasone in RRMM

A phase III study published in Annals of Hematology assessed the effect of adding continuous low-dose cyclophosphamide to the backbone regimen of bortezomib and low-dose dexamethasone, in patients with primary Refractory or Relapsed Multiple Myeloma (RRMM).

The open-label, randomized and controlled study was terminated early however, due to insufficient sample size. Descriptive results were published by Martin Kropff, Department of Haematology at Medizinische Klinik III, Osnabrück, Germany, and colleagues.

Conclusion

The study results for median TTP, ORR and disease progression did not indicate an additional benefit for the use of VCD compared with VD, for the treatment of primary RRMM patients. However, since the proposed sample size was not reached and the study was terminated early, further trials may be required to fully assess the clinical benefit of VCD. The safety profiles of both therapies were relatively similar with VCD showing slightly higher grade ≥3 peripheral neuropathy. The authors commented that the lack of benefit may be due to the use of a low-dose of cyclophosphamide and therefore investigating higher dosing schedules in a VCD combo may be of interest.

Jul 25, 2019

Jul 10, 2019

Jun 25, 2019

Professional society

The European School of Haematology (ESH) is a not for profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in haematology and related disciplines at the European level. ESH Conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical and therapeutic research in Haematology